Related Experiment Video
Updated: Aug 28, 2025

Signal Attenuation as a Rat Model of Obsessive Compulsive Disorder
Published on: January 9, 2015
Influence of selective serotonin reuptake inhibitors (SSRIs) in the development of bruxism
Andrea Wallem1, Natalia Felipe-Spada1, Jordi Tomàs-Aliberas1
1Department of TMJ, School of Dentistry, Universitat Internacional de Catalunya, Barcelona, Spain.
Objective:
To identify the relationship between the use of selective serotonin reuptake inhibitors (SSRIs) as pharmacological treatment and the development of bruxism.
Methods:
A systematic literature search was performed in PubMed and Scopus databases, which included articles written within the last 30 years. The working hypothesis was that there is a significant association between using SSRIs as an antidepressant medication and developing bruxism.
Results:
A total of four articles were included in the systematic review. All the articles are related to SSRI antidepressants and bruxism.
Conclusion:
The results indicate that there is an apparent association between SSRI drug treatment and the development of bruxism. The methods of evaluation and analysis were different in each article and cannot be considered conclusive; however, there is sufficient information to elucidate the impact of SSRI drugs on the development of bruxism.
Related Concept Videos
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Antidepressant Drugs: MAOIs and Other Agents
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Anxiolytic Drugs: Benzodiazepines and Buspirone
Drugs Affecting Neurotransmitter Release or Uptake

